The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)
Sponsor: Boston Scientific Corporation
Listed as NCT01665053, this PHASE3 trial focuses on Coronary Artery Disease and remains completed. Sponsored by Boston Scientific Corporation, it has been updated 17 times since 2012, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .